FEATURED EDITORIAL
Brain tumors are some of the most biologically complex and least improved indications. Biochemistry researcher and scientist Catherine Bladen, Ph.D., argues sustained focus are the keys to driving real-world progress.
- AI Drug Discovery Is Revealing The Preclinical Bottleneck
- Beyond Biologics: A Biophysical Approach To Crohn's Disease
- Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
- The Missing Data Set In Drug Discovery: Patient Experience As Decision Data
- Research Center Layout Helps Lower Barriers To Cross-Industry Collaboration
- What If The U.S. Government Stopped Funding Biotech?
- What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- Next‑Generation Omics: Latest Insights From A Growing Field
- 5 Takeaways From The Boston Open Science & Innovation Forum
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Flagship Pioneering And AWS Announce Collaboration To Accelerate Drug Discovery And Life Sciences Innovation
- Cogent Biosciences Announces Submission Of New Drug Application For Bezuclastinib In Gastrointestinal Stromal Tumors (GIST)
- Quantum Biopharma Submits Investigational New Drug (IND) Application To United States Food And Drug Administration (FDA) For Lucid-MS Phase Two Clinical Trial In Multiple Sclerosis
- NJ Bio, Inc. And Ajinomoto Bio Pharma Services Enter Into Collaboration To Strengthen Support For Antibody-Drug Conjugate Development
- Lupin Receives Tentative Approval From U.S. FDA For Sugammadex Injection
- OpenProtein.AI Expands Strategic Partnership With Boehringer Ingelheim To Advance AI-Driven Antibody Discovery
- Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company
- Zymeworks Receives U.S. FDA Fast Track Designation For ZW191, An Frα-Targeting Antibody-Drug Conjugate
- Jyong Biotech Updates The Potential Clinical Benefits And Advantages Of Its Plant-Derived Innovative Drug MCS®-2
- IBM Quantum Computer Accurately Simulates Real Magnetic Materials, Reproducing National Laboratory Data
ARCHIVED NEWSLETTER
- 04.07.26 -- What If The U.S. Government Stopped Funding Biotech?
- 04.04.26 -- Drug Discovery Online Best Of March
- 03.31.26 -- AI For NAM-Ready Drug Development: Turning Promise Into Trust
- 03.24.26 -- 5 Takeaways From The Boston Open Science & Innovation Forum
- 03.17.26 -- Hibernating Squirrels May Hold Clues To Treating Heart Failure
